

Description

CR technology dramatically extends the proliferation potential of epithelial cells in vitro. CRM medium supports the expansion of epithelial cells when used together with Propagenix irradiated feeder cells, Catalog No. PF-1100. The CRM medium contains nutrients and growth factors required to support cell growth when supplemented with Cholera toxin. Cholera toxin should be purchased separately to supplement medium.

CRM does not contain antibiotics.

Intended Use

For Research Use Only.

Storage Information

1. Store CRM at -20°C, protected from light, avoid repeated freeze/thaws.
2. Thaw CRM at 2° to 8°C.
3. Store thawed medium at 2° to 8°C, protected from light.
4. Once thawed, medium is stable for up to one month at 2° to 8°C.

Limitations

CRM culture medium is intended for growth of human epithelial cells using CR technology when it is used together with Propagenix irradiated feeder cells, Catalog No. PF-1100.

Supplement Medium

Prior to use, the CRM culture medium must be completed with Cholera toxin. Sigma Catalog No. C8052 and Enzo Life Sciences Catalog No. BML-G117-0001 are recommended commercial sources for Cholera toxin.

1. Aseptically rehydrate Cholera toxin in CRM to a final stock concentration of 1 mg/mL.
 - a) For example, rehydrate 1 mg Cholera toxin in 1 mL CRM medium.
2. Aseptically add 1 mg/mL Cholera toxin stock solution to 250 mL of CRM medium to a final concentration of 8.6-20 ng/mL.
 - a) To make 8.6 ng/mL final concentration, add 2.2 µL Cholera toxin stock solution prepared in step 1.
 - b) To make 20 ng/mL final concentration, add 5 µL Cholera toxin stock solution prepared in step 1.
3. The stock solution of Cholera toxin should be aliquoted and stored at 2° to 8°C for up to six months.

Quality Assurance

1. CRM Medium is tested prior to shipment to meet quality control specifications. Each lot is tested for sterility, pH, osmolality, endotoxin level, visually inspected for appearance, and functionally tested to support the growth of epithelial cells in CR Technology.
2. Additional information is available upon request.

Limited Use Label License (LULL)

Conditional Reprogramming (CR) Technology, covered under US Patent No. 9,279,106 (issued March 8, 2016), and subsequent patent applications pending in the US and other Jurisdictions.

Notice to End-Use Purchaser: This product is produced subject to an exclusive license to Propagenix Inc. for US Patents, patent applications, and foreign equivalents owned or controlled by Georgetown University, and related technology (the “CR Technology”). The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product, including its progeny and derivatives, and components of the product in research conducted by the buyer (whether the buyer is a non-profit or for-profit entity) as set forth in the accompanying product instruction manual. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made using this product or its components to a third party for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research under the terms of this Limited Use Label License and not for Commercial Purposes. Commercial Purposes means any activity by a party for financial consideration and may include, but is not limited to: (1) use of the product or its components, or a method claim of the foregoing patents in manufacturing; (2) use of the product or its components or a method claim of the foregoing patents to provide a fee-for-service activity; (3) use of the product for quality control or product release testing; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For products that are subject to multiple limited use label licenses, the most restrictive limited use label license terms apply. The research use limitation stated above shall not preclude the buyer from the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that (i) neither this product nor any of its components or a method claim of the foregoing patents was used in the manufacture of such product or conducting a fee-for-service activity, or (ii) the product or its components are not included in the therapeutic, prophylactic or diagnostic product. For information on obtaining additional rights to CR Technology, please contact support@propagenix.com.